INmune Bio INMB Stock
INmune Bio Price Chart
INmune Bio INMB Financial and Trading Overview
| INmune Bio stock price | 12.06 USD |
| Previous Close | 9.49 USD |
| Open | 9.44 USD |
| Bid | 0 USD x 1100 |
| Ask | 0 USD x 900 |
| Day's Range | 9.07 - 9.61 USD |
| 52 Week Range | 5.75 - 10.75 USD |
| Volume | 45.59K USD |
| Avg. Volume | 52.05K USD |
| Market Cap | 165.46M USD |
| Beta (5Y Monthly) | 1.9402 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.67 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.33 USD |
INMB Valuation Measures
| Enterprise Value | 134.67M USD |
| Trailing P/E | N/A |
| Forward P/E | -3.8902957 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 664.50653 |
| Price/Book (mrq) | 2.9925349 |
| Enterprise Value/Revenue | 540.853 |
| Enterprise Value/EBITDA | N/A |
Trading Information
INmune Bio Stock Price History
| Beta (5Y Monthly) | 1.9402 |
| 52-Week Change | 30.22% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 10.75 USD |
| 52 Week Low | 5.75 USD |
| 50-Day Moving Average | 7.92 USD |
| 200-Day Moving Average | 7.66 USD |
INMB Share Statistics
| Avg. Volume (3 month) | 52.05K USD |
| Avg. Daily Volume (10-Days) | 60.3K USD |
| Shares Outstanding | 17.95M |
| Float | 11.65M |
| Short Ratio | 25.27 |
| % Held by Insiders | 35.06% |
| % Held by Institutions | 9.92% |
| Shares Short | 1.03M |
| Short % of Float | 8.81% |
| Short % of Shares Outstanding | 5.71% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -10364.25% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -19.16% |
| Return on Equity (ttm) | -41.13% |
Income Statement
| Revenue (ttm) | 249K USD |
| Revenue Per Share (ttm) | 0.01 USD |
| Quarterly Revenue Growth (yoy) | -76.70% |
| Gross Profit (ttm) | 374K USD |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -26932000 USD |
| Diluted EPS (ttm) | -1.46 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 51M USD |
| Total Cash Per Share (mrq) | 2.84 USD |
| Total Debt (mrq) | 15.37M USD |
| Total Debt/Equity (mrq) | 27.79 USD |
| Current Ratio (mrq) | 5.532 |
| Book Value Per Share (mrq) | 3.081 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -14962000 USD |
| Levered Free Cash Flow (ttm) | -4655000 USD |
Profile of INmune Bio
| Country | United States |
| State | FL |
| City | Boca Raton |
| Address | 225 NE Mizner Blvd. |
| ZIP | 33432 |
| Phone | 858 964 3720 |
| Website | https://www.inmunebio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 10 |
INmune Bio, Inc., a clinical-stage immunology company, focuses on reprogramming the patient's innate immune system to treat cancer and neurodegenerative diseases. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma solid tumor and patients with high-risk myelodysplastic syndrome; INB03 to treat patients with cancers that express MUC4, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers; and XPro1595 for the treatment of Alzheimer's disease and Treatment Resistant Depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Q&A For INmune Bio Stock
What is a current INMB stock price?
INmune Bio INMB stock price today per share is 12.06 USD.
How to purchase INmune Bio stock?
You can buy INMB shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for INmune Bio?
The stock symbol or ticker of INmune Bio is INMB.
Which industry does the INmune Bio company belong to?
The INmune Bio industry is Biotechnology.
How many shares does INmune Bio have in circulation?
The max supply of INmune Bio shares is 15.53M.
What is INmune Bio Price to Earnings Ratio (PE Ratio)?
INmune Bio PE Ratio is now.
What was INmune Bio earnings per share over the trailing 12 months (TTM)?
INmune Bio EPS is -1.67 USD over the trailing 12 months.
Which sector does the INmune Bio company belong to?
The INmune Bio sector is Healthcare.
INmune Bio INMB included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Capital Market Composite RCMP | 114.55 USD — |
-2.27
|
— — | 114.09 USD — | 116.72 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}